000126541 001__ 126541
000126541 005__ 20250210083428.0
000126541 0247_ $$2doi$$a10.3390/ph16050772
000126541 0248_ $$2sideral$$a133991
000126541 037__ $$aART-2023-133991
000126541 041__ $$aeng
000126541 100__ $$0(orcid)0000-0003-2153-0417$$aAvedillo-Salas, Ana$$uUniversidad de Zaragoza
000126541 245__ $$aPrescribed drugs and self-directed violence: a descriptive study in the spanish pharmacovigilance database
000126541 260__ $$c2023
000126541 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126541 5203_ $$aSelf-inflicted violence is a major and growing public health problem and its prediction and prevention is challenging for healthcare systems worldwide. Our aim was to identify prescribed drugs associated with self-directed violent behaviors in Spain. A descriptive, longitudinal and retrospective study of spontaneous reports of adverse drug reactions corresponding to self-directed violence was recorded in the Spanish Pharmacovigilance Database (FEDRA®) from 1984 to 31 March 2021. A total of 710 cases were reported in the study period. The mean age was 45.52 years (range 1–94). There were no gender differences except in children, where most reports were of male children. The main therapeutic groups that were involved included drugs for the nervous system (64.5%) and anti-infectives for systemic use (13.2%). The most commonly reported drugs were varenicline, fluoxetine, lorazepam, escitalopram, venlafaxine, veralipride, pregabalin, roflumilast and bupropion. There were reports of montelukast, hydroxychloroquine, isotretinoin, methylphenidate, infliximab, natalizumab, ribavirin and efavirenz, which were less known to be involved in self-directed violence. This study shows that self-directed violence is a rare adverse drug reaction, and can be related to the use of some medicines. It is important for healthcare professionals to consider this risk in their clinical praxis, implementing person-centred approaches. Further studies are needed, considering comorbidities and potential interactions.
000126541 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000126541 590__ $$a4.3$$b2023
000126541 592__ $$a0.845$$b2023
000126541 591__ $$aPHARMACOLOGY & PHARMACY$$b69 / 354 = 0.195$$c2023$$dQ1$$eT1
000126541 593__ $$aPharmaceutical Science$$c2023$$dQ1
000126541 591__ $$aCHEMISTRY, MEDICINAL$$b20 / 72 = 0.278$$c2023$$dQ2$$eT1
000126541 593__ $$aDrug Discovery$$c2023$$dQ2
000126541 593__ $$aMolecular Medicine$$c2023$$dQ2
000126541 594__ $$a6.1$$b2023
000126541 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000126541 700__ $$aPueyo-Val, Javier$$uUniversidad de Zaragoza
000126541 700__ $$0(orcid)0000-0001-8064-8138$$aFanlo-Villacampa, Ana$$uUniversidad de Zaragoza
000126541 700__ $$0(orcid)0000-0002-7239-1966$$aNavarro-Pemán, Cristina$$uUniversidad de Zaragoza
000126541 700__ $$0(orcid)0000-0002-6485-1926$$aLanuza-Giménez, Francisco Javier$$uUniversidad de Zaragoza
000126541 700__ $$aIoakeim-Skoufa, Ignatios
000126541 700__ $$0(orcid)0000-0003-4629-6743$$aVicente-Romero, Jorge$$uUniversidad de Zaragoza
000126541 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000126541 773__ $$g16, 5 (2023), 772 [14 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000126541 8564_ $$s1713632$$uhttps://zaguan.unizar.es/record/126541/files/texto_completo.pdf$$yVersión publicada
000126541 8564_ $$s2610965$$uhttps://zaguan.unizar.es/record/126541/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126541 909CO $$ooai:zaguan.unizar.es:126541$$particulos$$pdriver
000126541 951__ $$a2025-02-10-08:31:23
000126541 980__ $$aARTICLE